| Guttman, Emma |
| Active, not recruiting | 4 | 44 | US | Dupilumab, Dupixent, Placebo | Icahn School of Medicine at Mount Sinai, Regeneron Pharmaceuticals, Sanofi | Keloid | 06/25 | 06/25 | | |
LEADS, NCT05436535: Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis |
|
|
| Recruiting | 4 | 600 | US | Dupilumab, Dupixent, Vanicream- Dupilumab-naïve, Triamcinolone Acetonide, Hydrocortisone, Vanicream- Active, Vanicream- Experienced Dupilumab | National Institute of Allergy and Infectious Diseases (NIAID) | Atopic Dermatitis | 05/25 | 10/25 | | |
NCT05608499: Duobrii Treatment of Acne Keloidalis Nuchae (AKN) |
|
|
| Active, not recruiting | 3 | 30 | US | Duobrii, halobetasol propionate and tazarotene, Placebo, Bryhali, halobetasol propionate | Icahn School of Medicine at Mount Sinai, Bausch Health Americas, Inc. | Acne Keloidalis Nuchae, AKN | 07/25 | 07/25 | | |
NCT05076006: Dual JAK1/TYK2 Inhibitor for Cicatricial Alopecia |
|
|
| Completed | 2 | 50 | US | PF-06700841, Brepocitinib, Placebo | Emma Guttman, Pfizer | Cicatricial Alopecia | 09/23 | 09/23 | | |
NCT06373458: Ritlecitinib in Patients With Keloids or Those Undergoing Keloidectomy |
|
|
| Recruiting | 2 | 30 | US | Ritlecitinib | Icahn School of Medicine at Mount Sinai, Pfizer | Keloid | 03/26 | 05/26 | | |
NCT06504160: Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2) |
|
|
| Not yet recruiting | 2 | 86 | US | ShA9 Topical Gel, Hydrocortisone Ointment, Clobetasol Ointment, Fluocinonide Ointment, Placebo (Vehicle) Topical Gel | National Institute of Allergy and Infectious Diseases (NIAID), Atopic Dermatitis Research Network (ADRN), Rho Federal Systems Division, Inc., PPD, Thermo Fisher Scientific Inc. | Atopic Dermatitis | 06/26 | 07/26 | | |
| Recruiting | 1 | 40 | US | Abrocitinib | Icahn School of Medicine at Mount Sinai | Food Allergy | 06/25 | 06/25 | | |
NCT01782703: Defining the Skin and Blood Biomarkers of Pediatric Atopic Dermatitis |
|
|
| Recruiting | N/A | 930 | US | | Northwestern University, Rockefeller University, Icahn School of Medicine at Mount Sinai | Atopic Dermatitis, Eczema | 12/25 | 12/25 | | |
NCT03417856: Defining the Skin and Blood Biomarkers of Ichthyosis |
|
|
| Recruiting | N/A | 200 | US | | Northwestern University, Icahn School of Medicine at Mount Sinai, Galderma R&D | Ichthyosis, Netherton Syndrome | 12/25 | 12/25 | | |
| Recruiting | N/A | 15000 | Europe, Canada, US | | Target PharmaSolutions, Inc. | Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Chronic Spontaneous Urticaria | 12/50 | 12/50 | | |
| Karalekas, Rachel |
LEADS, NCT05436535: Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis |
|
|
| Recruiting | 4 | 600 | US | Dupilumab, Dupixent, Vanicream- Dupilumab-naïve, Triamcinolone Acetonide, Hydrocortisone, Vanicream- Active, Vanicream- Experienced Dupilumab | National Institute of Allergy and Infectious Diseases (NIAID) | Atopic Dermatitis | 05/25 | 10/25 | | |
NCT06504160: Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2) |
|
|
| Not yet recruiting | 2 | 86 | US | ShA9 Topical Gel, Hydrocortisone Ointment, Clobetasol Ointment, Fluocinonide Ointment, Placebo (Vehicle) Topical Gel | National Institute of Allergy and Infectious Diseases (NIAID), Atopic Dermatitis Research Network (ADRN), Rho Federal Systems Division, Inc., PPD, Thermo Fisher Scientific Inc. | Atopic Dermatitis | 06/26 | 07/26 | | |
